Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil.

Autor: Clemens SAC; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.; Institute of Global Health, University of Siena, Siena, Italy., Folegatti PM; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Emary KRW; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Weckx LY; Department of Pediatrics, Universidade Federal de São Paulo, São Paulo, Brazil., Ratcliff J; Nuffield Department of Medicine, Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK., Bibi S; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., De Almeida Mendes AV; Escola Bahiana de Medicina e Saúde Pública, Brazil and ID'OR, Salvador, Brazil.; Hospital São Rafael, Salvador, Brazil., Milan EP; Universidade Federal do Rio Grande do Norte - UFRN, Natal, Brazil., Pittella A; Hospital Quinta D'Or, Rio de Janeiro, Brazil.; Instituto D'Or de Pesquisa e Ensino (IDOR), Rio de Janeiro, Brazil.; Universidade Unigranrio, Rio de Janeiro, Brazil., Schwarzbold AV; Clinical Research Unit, Department of Clinical Medicine, Universidade Federal de Santa Maria, Santa Maria, Brazil., Sprinz E; Infectious Diseases Service, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil.; Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil., Aley PK; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Bonsall D; Big Data Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Fraser C; Big Data Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Fuskova M; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Gilbert SC; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Jenkin D; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Kelly S; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Kerridge S; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Lambe T; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Marchevsky NG; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Mujadidi YF; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Plested E; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Ramasamy MN; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.; Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Simmonds P; Nuffield Department of Medicine, Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK., Golubchik T; Oxford Viral Sequencing Group, Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK., Voysey M; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK. merryn.voysey@paediatrics.ox.ac.uk., Pollard AJ; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK. Andrew.pollard@paediatrics.ox.ac.uk.

Publikováno v: Nature communications [Nat Commun] 2021 Oct 06; Vol. 12 (1), pp. 5861. Date of Electronic Publication: 2021 Oct 06.